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Polycystic kidney disease in adults (APKD) is an autosomal dominant trait which shows a high penetrance. It is a common clinical abnormality affecting 80/100 000 of the general population' and in many renal replacement therapy programmes represents the third commonest cause of chronic renal failure. 2 Many patients do not present until the onset of symptoms, commonly after the age of 30, by which time target organ damage from hypertension may be severe.3 Diagnosis before clinical presentation can be made by ultrasound, computed tomography, or intravenous urography with nephrotomography. As ultrasound does not require the use of radiation or the injection of contrast medium, it is to be preferred as a screening method. The sensitivity of detection is limited in the younger age groups, being only 22% in the 0 to 9 year age group, but rising to 86% in the 20 to 29 year age group.4 Satisfactory genetic counselling for members of affected families can therefore be difficult,5 which has prompted the search for a closely linked genetic marker to assist in the prediction of polycystic kidney disease. Previous genetic linkage studies have looked at the relationship of histocompatibility complex (HLA) and certain blood group antigens and have excluded close linkage to these loci.' 6 We initiated a broad based genetic linkage study using a variety of polymorphic markers, which at the outset included blood groups, enzyme and other protein markers, and DNA probes mapped to the full range of human chromosomes. However, during the early phase of our study, Reeders et af7 8 reported genetic linkage between APKD and a highly polymorphic DNA locus situated 8 kb 3' to the a globin cluster and the phosphoglycolate phosphatase (PGP) locus on chromosome 16 . Here we present therefore the results of our analysis of three polymorphic markers 457 whose loci are all reported to be on chromosome 16 (PGP, GPT, and HP).9
Methods
One hundred and eighty-four relatives of 12 APKD probands were admitted to the study after giving informed consent, as approved by the local Ethical Committee. Each member was vistited at home and 50 ml EDTA anticoagulated blood was taken by venepuncture for measurement of nine blood group antigens, 20 plasma, red and white blood cell isoenzymes, and for extraction of DNA. Blood for separation of red and white cells was centrifuged at 3000 rpm for 10 minutes and the plasma and buffy coat were removed. The red cells were washed three times in 0 9% sodium chloride and stored at -70C before isoenzyme electrophoresis.
ISOENZYME ELECTROPHORESIS
Plasma and washed red blood cells, lysed by freezing and thawing, were used for the analyses using previously described methods for PGP and GPT and for HP. "l PGP shows six electrophoretically distinguishable phenotypes attributable to three polymorphic alleles, PGP1, PGP2, and PGP3, which occur in the European population at frequencies of 0-826, 0-129, and 0-045, respectively.'2 GPT shows three electrophoretic phenotypes associated with alleles GPT1 and GPT2 with frequencies 0-52 and 0-47 respectively.'3 Haptoglobin shows three electrophoretic phenotypes associated with alleles HP1 and HP2 with frequencies of about 0-4 and 0-6 respectively (Galton Laboratory data). No definite recombinations were observed between PGP and APKD in these families so that the maximum likelihood genetic distance between these loci is estimated to be at a recombination fraction of zero, with a lod score of 5-5. The result is therefore statistically significant and shows that the PGP polymorphism does indeed provide a potentially useful predictive test for APKD. However, before PGP or 3'HVR is applied clinically, a number of issues need to be resolved.
Firstly, it will be necessary to obtain a larger sample of informative families on which to base an accurate estimate of the genetic distance between PGP and APKD. The latter will form the basis for risk estimation in genetic counselling, whether for preclinical detection or for prenatal diagnosis. The confidence limits for the recombination fraction between APKD and PGP in this study extend from 0 to 0 18, implying that a predictive error as high as 18% is possible. When these results are combined with those of Reeders et al,8 the maximum likelihood value of the recombination fraction remains at zero (99% confidence limits of 0.09) with a lod score of 13 71 (sexes combined).
Secondly, the possibility of genetic heterogeneity of the locus must be considered. This is true of virtually all genetic disease in which the biochemical defect is unknown, particularly when there is a high prevalance, as in adult polycystic kidney disease.' However, at present, combined results with the 3' HVR probe indicate that the disease is likely to be genetically homogeneous.'7
Thirdly, it will be important to establish the order of the PGP, 3'HVR, and APKD loci on chromosome 16 . Error in predictive counselling on the basis of a linked genetic marker arises from recombination between marker and disease locus. As discussed above, accurate estimation of the recombination fraction is essential, but predictive error can be reduced considerably by the simultaneous use of markers that are located on either side of the disease gene (bridging markers). It remains to be determined whether PGP and a globin bridge the APKD locus.
How useful is the PGP polymorphism likely to be in prenatal diagnosis? PGP has been detected in all tissues examined so far.12 It is therefore possible that it is also present in amniocytes and chorionic villus samples, although it is not yet clear whether at a sufficiently high level for reliable detection.
There is some controversy surrounding the precise location of the GPT locus since linkage has been reported both to chromosome 16 and to other chromosomes.9 A substantial amount of new data has been reported recently which still does not resolve the issue but shows that there is 44% recombination with PGP, which is consistent with our failure to detect linkage between APKD and GPT. The HP locus has been assigned to the long arm of chromosome 16 (16q21-*q22)9 and shows at least 35% recombination with PGP. The failure to find evidence for linkage between HP and APKD in this study is therefore consistent both with APKD being close to PGP on the short arm and with HP and PGP being well separated.'8 A number of clinical issues arose in the course of the study that highlight the need for reliable predictive markers in APKD. One problem arose when subjects at risk for APKD were found to have only one or two renal cysts, raising doubts as to their genetic status. Misclassification of normals as being affected will lead to inaccurate genetic mapping data and seriously compromise genetic counselling. The diagnosis was only made, therefore, if certain criteria were met on renal ultrasound examination. Because single and multiple cysts occur in normal subjects and their prevalence increases with age,19 scans were only considered to be positive if two or more transonic cysts with well defined back walls and some acoustic enhancement were seen in one kidney and a single cyst in the other. In early cases, when the cysts are small (<6 to 8 mm), they may not fulfil these criteria for technical reasons. In these cases, small, abnormal, cyst-like anechoic or very hyperechoic areas were considered to represent cysts provided that they did not correspond in size, shape, or position to the renal pyramids. However, subjects at risk showing only one or two clearly defined renal cysts can cause considerable diagnostic problems that would be greatly relieved by the availability of genetic markers.
Another issue that became increasingly apparent as the study progressed was the need for genetic counselling in APKD families, as reported by Sahney et 
